News

OctoPlus is a European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries. As per the agreement OctoPlus is expected to

SYN115 is an orally bioavailable, potent and selective adenosine A2a receptor antagonist, which enters the brain and modulates regions associated with motor and non-motor function. Biotie obtained development

The company has submitted another patent application covering protection for the T36 formula in combination with anesthetics, analgesics and anti-inflammatories as a treatment for a range of topical

Elidel is an immuno-suppressant which helps to slow down the growth of atopic dermatitis (eczema) on the skin. As per the terms of the agreement, Meda is responsible

Astrazeneca said the safety and effectiveness of Vandetanib were proved in a single randomised international study of 331 patients with late-stage medullary thyroid cancer, who were selected to

Horizant is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. It is not recommended for patients who are required to sleep during the daytime

The global Phase III trial for Multikine was started in the US in late December 2010. CEL-SCI expects to commence the trial in other countries around the world

The first shipment of the product has triggered a milestone payment under the license, manufacturing and supply agreement with Precision Dose and its wholly owned subsidiary TAGI Pharma.

The agreement was made for the discovery of new cationic lipids employed in lipid nanoparticles (LNPs) for the systemic delivery of RNAi therapeutics. Alnylam has funded the research